From the OICR website:
"The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery to create a pipeline of validated cancer targets and first-in-class or best-in-class, novel, selective lead molecules (small molecules or biologics) to attract partnerships and/or investment for further preclinical and clinical development. To generate a sustainable pipeline, CTIP will support projects that aim to provide increasing evidence of target validation and disease association using data from knowledgebases, functional assays, and drug screening in relevant in vitro and in vivo models of the cancer type of interest.
Early Validation projects: Deliver robust translational evidence that a Target-of-Interest (TOI) is associated to a specific cancer type based on data from knowledge bases and from studies demonstrating that perturbation of the TOI in relevant cell-based or higher order models produces anti-cancer effects sufficient to trigger a drug discovery campaign.
Funding available: Up to $150,000 per year for a maximum of two years.
Early Accelerator projects: Deliver a validated primary assay to enable initial screening of molecules against a defined target. Preliminary evidence of linearity of results between the primary assay and supporting secondary assays under development is also required.
Funding available: Up to $150,000 for a maximum of one year.
Late Accelerator projects: Deliver confirmed Hit molecules against a defined target using validated primary, secondary and orthogonal assays for screening.
Funding available: Up to $500,000 per year for a maximum of two years.
OICR invites applications from investigators at Ontario academic centres, hospital research institutes, or other government research institutions. CTIP funding is only tenable in Ontario. For-profit entities are not eligible to apply."